Edessa vs PCOS Sisters
A hundred dollars and thirty-nine states separate two sellers that both hold their rate.
Edessa
Editorial
$179/mo
Compounded semaglutide in both an injection and a tablet, plus compounded tirzepatide, each with a three-term plan table. The injection is $179 for one month; the homepage's $135 is the six-month prepay rate. Rates are stated to hold flat as the dose rises.
Pick it for: Buyers who want the lower held rate and broad coverage
PCOS Sisters
Editorial
$249/mo
A GLP-1 program built around polycystic ovary syndrome, charging one $150 monthly management fee whether the prescription is compounded semaglutide or compounded tirzepatide. A $99 monthly membership is required to hold a prescription, so the billed figure is $249 for either molecule. Coverage is stated across 12 states and the rate holds at every dose.
Pick it for: Buyers in its twelve states who want a service built around PCOS
Our verdict
Edessa opens at $179 across a wide footprint; PCOS Sisters opens at $249 in twelve states. Both state a flat rate, so the comparison is coverage and money rather than terms.
What actually separates them
Edessa and PCOS Sisters state different things about published price and where you can use it. Everything else they publish, they publish the same way.
PCOS Sisters costs $70 more than Edessa — 39% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $2,148 at Edessa against $2,988 at PCOS Sisters — a difference of $840.
| Edessa | PCOS Sisters | |
|---|---|---|
| Published price | $179/mo | $249/mo |
| Where you can use it | All 50 states and the District of Columbia | 12 states |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.